95.38 +0.17 (0.18%)
After hours: 4:10PM EDT
|Bid||94.50 x 800|
|Ask||110.96 x 1000|
|Day's Range||94.51 - 96.14|
|52 Week Range||87.35 - 153.99|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Solid Biosciences (SLDB) incurred a net loss of $17.98 million in the second quarter of 2018, which compares to a net loss of $11.31 million in the second quarter of 2017, translating to a net loss per share of $0.52 in the second quarter of 2018. Its net loss per share was $0.66 in the second quarter of 2017. The decrease in net loss per share was due to an increase in the company’s outstanding shares, which increased from 17.04 million in the second quarter of 2017 to 34.45 million in the second quarter of 2018.
On September 13, Dicerna Pharmaceuticals (DRNA) stock rose 7.71% to $16.62 from its previous day’s close of $15.43. In the trial, Dicerna’s lead drug candidate, DCR-PHXC, showed that it was capable of bringing urinary oxalate levels to a normal or near-normal range in individuals with primary hyperoxaluria type 1 and hyperoxaluria type 2. The company is conducting studies with DCR-PHXC and investigating its potential as a therapy for all forms of hyperoxaluria.
Sarepta Therapeutics (SRPT) incurred a net loss of $109.27 million in the second quarter of 2018 compared to a net loss of $63.05 million in Q2 2017. Its net loss per share was $1.15 in the second quarter of 2017. Despite the surge in revenues, Sarepta’s net loss widened due to higher operating expenses, which increased from $98.35 million in the second quarter of 2017 to $176.96 million in the second quarter of 2018.
In the second quarter, Alkermes (ALKS) reported revenues of $304.6 million—compared to $218.8 million in the second quarter of 2017, which reflects ~39% growth year-over-year. In the second quarter, Alkermes generated revenues of $128.2 million as manufacturing and royalty revenues. Alkermes reported revenues of $109.8 from product sales in the second quarter—compared to $88.7 million in the second quarter of 2017.
Alkermes (ALKS) anticipates the net revenues in fiscal 2018 to be $957.0 million–$1.0 billion. Alkermes estimates the GAAP (generally accepted accounting principle) net income to be -$210.0 million to -$240.0 million, while the GAAP EPS is expected to be -$1.35 to -$1.55. Alkermes expects the non-GAAP net income to be between -$10 million and $20 million. The company also estimates the non-GAAP EPS to be between -$0.06 and $0.12.
Here's a look at the Boston biotech news you missed during your summer vacation: Alnylam gets historic FDA approval for first drug Cambridge's Alnylam Pharmaceuticals (Nasdaq: ALNY) received FDA approval for its first drug on Aug. 10, a first-ever treatment for a rare genetic disease that uses RNA interference to silence genes. The drug treats hereditary ATTR amyloidosis, which causes the liver to protein abnormal proteins that impede nervous system and organ functions. Marketed under the name Onpattro, it's the first RNA interference drug to be approved by the FDA.
Alnylam's (ALNY) Onpattro, the first ever RNA interference (RNAi) therapeutic, has been granted marketing authorization by the European Commission.
Yesterday, Alnylam Pharmaceuticals (ALNY) rose ~19% in afternoon trading and closed the day ~16.3% higher than the previous day’s closing price. The rise was triggered by the news of positive phase three study data from Pfizer (PFE) for rival drug tafamidis for the treatment of transthyretin amyloid cardiomyopathy (or ATTR-CM). Alnylam Pharmaceuticals’ ATTR therapy Onpattro (patisiran) was approved by the FDA on August 10, 2018.
As stocks surged on positive trade news, Tesla slipped after calling off plans to go private, and Pfizer released information that caused big movements in some biotech stocks.
Multiple pharma stocks are making sympathy moves Monday in reaction to data released at the 2018 European Society of Cardiology Congress in Munich, Germany. Pfizer Inc. (NYSE: PFE ) shares are trading ...
Pfizer Inc. (PFE) shares rose just under 1% in Monday premarket trade after the company announced positive results from a late-stage trial of its drug tafamidis, which is being developed for the rare disease transthyretin amyloid cardiomyopathy. The Pfizer results were strong but "we see the door open to ALNY given key details of the study: 1) 20 mg not differentiated from 80 mg, and 2) more limited efficacy in the ATTRm population (vs wild-type) and would not be surprised to see ALNY shares trade up," said EvercoreISI analyst Josh Schimmer and Steven Breazzano, who went on to say that two rival therapies, Alnylam Pharmaceuticals Inc.'s (ALNY) patisiran and Ionis Pharmaceuticals Inc. (IONS) and Akcea Therapeutics Inc.'s (AKCA) inotersen, "will generally be safe in the neuropathy population." Alnylam shares rose 4.3% in premarket trade while Ionis and Akcea shares were inactive.
Pfizer Inc.’s pipeline may finally be delivering. A new study shows that patients with a rare condition that can lead to heart failure lowered their risk of dying by 30 percent after being treated with Pfizer’s tafamidis. The finding could give the biggest U.S. drugmaker another potential blockbuster medicine and challenge a biotech startup marketing its own groundbreaking treatment for the same disease.
Alnylam Pharmaceuticals (ALNY) completes enrollment in the phase III ENVISION study ahead of schedule of its pipeline candidate, givosiran.
The biotech sector witnesses a pretty low key week with a handful of regulatory updates. Regeneron secures an FDA approval for the label expansion of its key drug Eylea.
After 16 years of development and $2.5 billion in investments, Alnylam Pharmaceuticals Inc. (ALNY) brought the world's first RNAi treatment, known as Onpattro, to market. Despite this accomplishment, the company did not see a significant jump in its stock following the Food and Drug Administration's approval. In fact, Alnylam is down approximately 6% over the last three months.